Crescent Biopharma, Inc.
CBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCrescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. The company carries a $775.6M market cap, placing it firmly in the small-cap category. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Market Cap
$775.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.94
EPS (TTM)
$-0.14
EPS (Fwd)
$-2.63
ROE
—
ROA
—
Cash
$171.6M
Total Debt
$1.4M
Free CF
—
52W Change
66.4%
Annual Financials
Cash vs Debt
Where CBIO stands vs its 150-day and 200-day moving averages
As of the August 7, 2026 close, CBIO finished 5.32% above its 150-day moving average ($15.60) and 9.83% above its 200-day moving average ($14.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBIO overbought or oversold?
At the August 7, 2026 close, CBIO's RSI(14) was 57.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $171.6M in cash comfortably exceeding the $1.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods.
With cash comfortably exceeding debt, CBIO has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.